Navigation Links
Changing Trends Regarding Insurance Cover For Weight Reduction Surgery

Bariatric surgery is a term derived from the Greek words: ''weight'' and ''treatment.'' Bariatric surgical procedures are major gastrointestinal operations that either seal off most of the stomach to reduce// the amount of food one can eat or rearrange the small intestine to reduce the calories the bodies can absorb. It is a collective term given to the various surgical options available for treatment of obesity.

Bariatric surgery is now becoming common place with more and more number of people interested in losing weight in a drastic way. As the demand for bariatric surgery continues to increase, employers and insurers are increasingly forced to make or revisit decisions about whether or not to provide insurance coverage for the cost of the procedure.

Several studies have been conducted on whether an insurance cover for such type of a surgery is necessary. It is estimated that the return on investment associated with an employer’s decision to provide some level of coverage for bariatric surgery and the demand for such surgeries is based on various out-of-pocket costs.

In a recent study conducted, it has been found out that nearly 9 percent of all full-time employees are eligible for bariatric surgery based on existing guidelines. Because of their high medical costs and increased absenteeism, approximately two-thirds of costs attributable to obesity are incurred by those eligible for bariatric surgery. It would likely take between five and 10 years for an employer to recover the full cost of the surgery.

The second study used an Internet survey of obese individuals to determine that about 150,000 bariatric procedures per year would be demanded by those with private health insurance at an out-of-pocket price of $25,000. Even when fully covered by insurance, the results suggest that demand among those with private insurance would not exceed about 375,000 procedures per year among full time employees. These estimates allow insurer
'"/>




Page: 1 2

Related medicine news :

1. Changing stem cells to liver cells
2. Changing Partners may put Expectant Mothers at Risk
3. Stem Cell Research - Changing Wishes to Possibilities and Possibilities to Reality
4. Weight-Loss Surgeries Changing Lives
5. Changing Trends In Family Health Practice
6. Changing Food Habits: Fodder For Thought
7. Trendsetters: Little girls fast track into ladies even before they know it
8. Changing Trends In Family Health Practice
9. New Trends in Drug Abuse Among Teenage Girls
10. Researchers Present Data Regarding The Efficiency Of Herbs
11. Leeches Provide Clues Regarding The Prevention Of Heart Disease
Post Your Comments:
(Date:5/22/2008)..., N.C. -- A new study by Duke University researche...O) system in the life of a cell plays a key role i...ve treatment of illnesses such as heart disease an...a major biological signaling pathway that has been...s, and it is linked to cancer and other diseases w...
(Date:5/22/2008)...entation Will be Webcast Live and Archived on Comp...-FirstCall/ -- Vanda Pharmaceuticals,Inc. (Nasdaq:...he development,and commercialization of clinical-s... disorders, today announced that Mihael H. Polymer...r a corporate presentation on,Wednesday, May 28, 2...
(Date:5/22/2008)... BEACH, Calif., May 22 /PRNewswire/ -- Whether you... short getaway, if you are an older adult,there ar...re a healthy,trip. According to Timothy Schwab, M....se ten tips for seniors apply whether you,re plann...s away., 1. Discuss travel plans with your ...
(Date:5/22/2008)...udy suggests threat of starvation triggers the swi...) -- New animal research suggests the body,s biolo... the rise and fall of the sun, can be overridden i..., The finding is based on work with mice and ha...cations are that, when faced with starvation, the ...
Breaking Medicine News(10 mins):Health News:Major 'missed' biochemical pathway emerges as important in virtually all cells 2Health News:Major 'missed' biochemical pathway emerges as important in virtually all cells 3Health News:Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference 2Health News:SCAN Health Plan Offers Seniors Ten Tips for Safe and Healthy Travel 2Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 2Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 3Health News:'Food Clock' May Override Master Sleep Clock in Times of Duress 4
...oral treatment for smoking, called Zyban. The pil...y the first product aimed at stopping smoking and ...wspersons, Mr. Kalyanasundaram, Director (Pharmace...ete treatment osts about Rs. 5000 and takes about ...
... of cancer, is avenged now by the new proven effec...dermal growth factor receptor tyrosine kinase inhi... in patients with advanced non-small cell lung can...ation with standard chemotherapy agents after segm...
...ls of S-nitrosoalbumin, a naturally occuring chemi...ngerous complication of pregnancy affects 10% of a...en into a life threatening condition called Eclamp...ng pregnancy. The research was led by Dr.Valerian...
... embarking on an exercise to grade hospital and me.... Sanjiv Malik, Honorary Secretary-General of the ...nce with ORGMARG to create a database on all the m...it allopathy or homeopathy, he said. The process ...
Other Medicine News:
(Date:5/21/2008)...1 /- Pressure,BioSciences, ... scientists,from the New York University (NYU) Sch... the Harvard School of Public Health made presenta... patented pressure cycling,technology (PCT) at thr....,There were three oral presentations and four pos...
(Date:5/21/2008)...an Urological Association Annual Meeting -, SEATT.../ -- Researchers,from Dendreon Corporation (Nasdaq...rating the potential of D-3263, Dendreon,s orally ...(a transmembrane cation channel protein also,known... (BPH)., The abstract (#2041), "Preclinical Valid...
(Date:5/20/2008)...ay 21 /- Today at the,World...e entitled "New,Perspectives in Atrial Fibrillatio...linical Cardiology, St George,s University of Lond...ced ATHENA clinical trial,results, as the way forw...n, the most common form of cardiac arrhythmia., T...
(Date:5/20/2008)...ed today at Digestive Disease Week -, CAMBRIDGE, ...--,Ironwood Pharmaceuticals, Inc. (formerly Microb...X ) today announced the presentation of data,from ...olled study,assessing the safety and efficacy of l...CC). Analysis of these data indicate that linaclot...
Breaking Medicine Technology:Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 2Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 3Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City 4Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 2Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 4Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 6Nucletron Announces Oncentra 28R 29 Brachy Treatment Planning Solution for Multimodality Environment 4906 1Nucletron Announces Oncentra 28R 29 Brachy Treatment Planning Solution for Multimodality Environment 4906 2Terumo Heart Summarizes Results of DuraHeart 28TM 29 LVAS Implants 1913 1Terumo Heart Summarizes Results of DuraHeart 28TM 29 LVAS Implants 1913 2Will you be misdiagnosed 3F how diagnostic errors happen 17851 1Will you be misdiagnosed 3F how diagnostic errors happen 17851 2Will you be misdiagnosed 3F how diagnostic errors happen 17851 3American Chemical Societys Weekly PressPac April 23 2008 3076 1American Chemical Societys Weekly PressPac April 23 2008 3076 2American Chemical Societys Weekly PressPac April 23 2008 3076 3American Chemical Societys Weekly PressPac April 23 2008 3076 4American Chemical Societys Weekly PressPac April 23 2008 3076 5American Chemical Societys Weekly PressPac April 23 2008 3076 6American Chemical Societys Weekly PressPac April 23 2008 3076 7American Chemical Societys Weekly PressPac April 23 2008 3076 8
...r 7, 2007 - Gemin X,announced today that a report ...od demonstrated that its lead compound, GX15-070,(...inst,patient-derived multiple myeloma tumor cells ...ts when used as a combination therapy.,GX15-070 is... all,relevant members of the Bcl-2 protein family,...
...erican College of,Cardiology,s Scientific Session ...irstCall/ -- CV,Therapeutics, Inc. announced today...N TIMI-36 study of ranolazine shows there was no,a...n ranolazine.,The study did not meet the primary e...,s special protocol assessment,agreement with the ...
Other Medicine Technology:Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3
ORTHOSET Radiopaque Bone Cement consists of a two component system: a sterile,ampule containing bone cement liquid within a blister pack, and a sterile polyethylene bag,containing bone cement pow
Low viscosity bone cement without antibiotics for syringe use with an average setting time of approx. 7-9 Min., 40g of powder and 14.6g of liquid.
...eoscope represents new thinking to address common ... eliminating a 5.85 mm diameter outer arthroscope ...diameter Videoscope has superior access and mobili...and especially in the elbow and ankle. In conjunct...
... llifestly of hypertensive and hopotensive patient...sociated with blood pressure monitoring conducted ...ep instrument, it enables physicians to conduct ro...f ther patient's homes. With its built-in proprie...
Medicine Products: